As the debate over abortion access continues to escalate, a new front has emerged in the battle over reproductive rights. Pharmaceutical companies are now facing pressure to change the delivery system of mifepristone, a key medication used in medical abortions. However, altering the way this medication is dispensed raises a host of complex questions, from practical concerns about patient access and safety to medical worries about the potential impact on the effectiveness of the treatment. As lawmakers and advocates on both sides of the issue weigh in, the future of mifepristone's delivery system hangs in the balance, with far-reaching implications for the millions of women who rely on the medication each year.
Targeting mifepristone’s delivery system raises practical and medical questions that extend far beyond abortion
